Optimizing methotrexate therapy in rheumatoid arthritis: A systematic literature review

被引:26
作者
Mouterde, Gael [1 ]
Baillet, Athan [2 ]
Gaujoux-Viala, Cecile [3 ]
Cantagrel, Alain [4 ]
Wendling, Daniel [5 ]
Le Loet, Xavier [6 ]
Schaeverbeke, Thierry [7 ]
机构
[1] Univ Montpellier I, Lapeyronie Hosp, Serv Immuno Rhumatol, UMR 5535, F-34295 Montpellier 5, France
[2] Clin Univ Rhumatol, CHU Hop Sud, F-38434 Echirolles, France
[3] Univ Paris 06, CHU Pitie Salpetriere, Serv Rhumatol, F-75013 Paris, France
[4] CHU Rangueil, Serv Rhumatol, F-31059 Toulouse 9, France
[5] CHU Jean Minjoz, Serv Rhumatol, F-25000 Besancon, France
[6] Univ Rouen, Rouen Univ Hosp, Serv Rhumatol, INSERM,U905, F-76030 Rouen, France
[7] CHU Pellegrin, Serv Rhumatol, F-33076 Bordeaux, France
关键词
Rheumatoid arthritis; Methotrexate; Treatment strategy; Dosage; Route of administration; Systematic literature review; MODIFYING ANTIRHEUMATIC DRUGS; PARENTERAL METHOTREXATE; COMBINATION THERAPY; DOSE-ESCALATION; DOUBLE-BLIND; RECOMMENDATIONS; MANAGEMENT; STRATEGY; EFFICACY; TRIAL;
D O I
10.1016/j.jbspin.2011.01.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe the means of optimizing methotrexate therapy for rheumatoid arthritis in daily clinical practice, based on a systematic literature review. Methods: We systematically reviewed the literature by searching the PubMed, Embase, and Cochrane databases and reviewing communications to ACR and EULAR meetings for studies on methotrexate starting dosages, dosage increment sizes and intervals, maximum dosages, and routes of administration in patients with rheumatoid arthritis. We used an appropriate scoring system to assess the methodological quality of each selected study. Results: We identified 519 studies of which 11 were selected based on the titles and abstracts then on the full-length articles. Methotrexate was optimally effective when started in a high dosage (more than 10 mg/week orally) that was subsequently increased by 5 mg/month up to 25-30 mg/week, 1 with appropriate adjustments based on clinical disease activity and tolerance of each patient. For a given methotrexate dosage, parenteral administration was more effective and produced fewer gastrointestinal adverse effects than oral administration. Conclusion: The information supplied by this systematic review support higher starting dosage, an intensive dosage increase schedule and recourse to parenteral administration in case of unresponsiveness or intolerance to oral methotrexate. They should improve the management of patients given methotrexate therapy for rheumatoid arthritis. (C) 2011 Published by Elsevier Masson SAS on behalf of the Societe Francaise de Rhumatologie.
引用
收藏
页码:587 / 592
页数:6
相关论文
共 36 条
[1]  
Anderson JJ, 2000, ARTHRITIS RHEUM, V43, P22, DOI 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO
[2]  
2-9
[3]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[4]  
Bakker MF, 2008, ARTHRITIS RHEUM, V58, pS764
[5]   The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Where the rubber meets the road [J].
Bathon, Joan M. ;
Cohen, Stanley B. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (06) :757-759
[6]   Methotrexate: Still the anchor drug in RA treatment [J].
Bijlsma, Johannes W. J. ;
Jacobs, Johannes W. G. .
JOINT BONE SPINE, 2009, 76 (05) :452-454
[7]   Parenteral methotrexate should be given before biological therapy [J].
Bingham, SJ ;
Buch, MH ;
Lindsay, S ;
Pollard, A ;
White, J ;
Emery, P .
RHEUMATOLOGY, 2003, 42 (08) :1009-1010
[8]   Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis [J].
Braun, J. ;
Kaestner, P. ;
Flaxenberg, P. ;
Waehrisch, J. ;
Hanke, P. ;
Demary, W. ;
von Hinueber, U. ;
Rockwitz, K. ;
Heitz, W. ;
Pichlmeier, U. ;
Guimbal-Schmolck, C. ;
Brandt, A. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (01) :73-81
[9]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[10]   Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].
Clair, EWS ;
van der Heijde, DMFM ;
Smolen, JS ;
Maini, RN ;
Bathon, JM ;
Emery, P ;
Keystone, E ;
Schiff, M ;
Kalden, JR ;
Wang, B ;
DeWoody, K ;
Weiss, R ;
Baker, D .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443